This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shi, J. Articles by Hoffman, R. Search for Related Content PubMed PubMed Citation Articles by Shi, J. Articles by Hoffman, R.

Effects of Chromatin-Modifying Agents on CD34⁺ Cells from Patients with Idiopathic Myelofibrosis

¹ Section of Hematology/Oncology, Departments of Medicine and ² Pathology, University of Illinois College of Medicine, Chicago, Illinois

Requests for reprints: Ronald Hoffman, Section of Hematology/Oncology, Department of Medicine, College of Medicine Research Building, Room 5053 (M/C 704), 909 South Wolcott Avenue, Chicago, IL 60612. Phone: 312-413-9309; Fax: 312-355-0685; E-mail: ronhoff{at}uic.edu.

Idiopathic myelofibrosis (IM) is likely the consequence of both the acquisition of genetic mutations and epigenetic changes that silence critical genes that control cell proliferation, differentiation, and apoptosis. We have explored the effects of the sequential treatment with the DNA methyltransferase inhibitor, decitabine [5-aza-2'-deoxycytidine (5azaD)], followed by the histone deacetylase inhibitor, trichostatin A (TSA), on the behavior of IM CD34⁺ cells. Unlike normal CD34⁺ cells where 5azaD/TSA treatment leads to the expansion of CD34⁺ cells and marrow-repopulating cells, treatment of IM CD34⁺ cells results in a reduction of the number of total cells, CD34⁺ cells, and assayable hematopoietic progenitor cells (HPC). In IM, HPCs are either heterozygous or homozygous for the JAK2V617F mutation or possess wild-type JAK2 in varying proportions. Exposure of IM CD34⁺ cells to 5azaD/TSA resulted in a reduction of the proportion of JAK2V617F-positive HPCs in 83% of the patients studied and the reduction in the proportion of homozygous HPCs in 50% of the patients. 5azaD/TSA treatment led to a dramatic reduction in the number of HPCs that contained chromosomal abnormalities in two JAK2V617F-negative IM patients. IM is characterized by constitutive mobilization of HPCs, which has been partly attributed to decreased expression of the chemokine receptor CXCR4. Treatment of IM CD34⁺ cells with 5azaD/TSA resulted in the up-regulation of CXCR4 expression by CD34⁺ cells and restoration of their migration in response to SDF-1. These data provide a rationale for sequential therapy with chromatin-modifying agents for patients with IM. [Cancer Res 2007;67(13):6417–24]

This article has been cited by other articles:

				X. Wang, W. Zhang, T. Ishii, S. Sozer, J. Wang, M. Xu, and R. Hoffman Correction of the Abnormal Trafficking of Primary Myelofibrosis CD34+ Cells by Treatment with Chromatin-Modifying Agents Cancer Res., October 1, 2009; 69(19): 7612 - 7618. [Abstract] [Full Text] [PDF]

				T. Ishii, J. Wang, W. Zhang, J. Mascarenhas, R. Hoffman, Y. Dai, N. Wisch, and M. Xu Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders Blood, June 4, 2009; 113(23): 5942 - 5950. [Abstract] [Full Text] [PDF]

				S. Sozer, M. I. Fiel, T. Schiano, M. Xu, J. Mascarenhas, and R. Hoffman The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome Blood, May 21, 2009; 113(21): 5246 - 5249. [Abstract] [Full Text] [PDF]

				X. Wang, W. Zhang, T. Ishii, S. Sozer, J. Wang, M. Xu, and R. Hoffman Correction of the Abnormal Trafficking of Primary Myelofibrosis CD34+ Cells by Treatment with Chromatin Modifying Agents Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 101 - 101. [Abstract]

				J.-J. Lataillade, O. Pierre-Louis, H. C. Hasselbalch, G. Uzan, C. Jasmin, M.-C. Martyre, M.-C. Le Bousse-Kerdiles, and on behalf of the French INSERM and the European EU Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence Blood, October 15, 2008; 112(8): 3026 - 3035. [Abstract] [Full Text] [PDF]

				R. L. Levine and D. G. Gilliland Myeloproliferative disorders Blood, September 15, 2008; 112(6): 2190 - 2198. [Abstract] [Full Text] [PDF]

				A. Rambaldi, T. Barbui, and G. Barosi From Palliation to Epigenetic Therapy in Myelofibrosis Hematology, January 1, 2008; 2008(1): 83 - 91. [Abstract] [Full Text] [PDF]